(Q40484043)

20 September 2017

title

Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies (English)

1 reference

20 September 2017

0 references

1 reference

Sang-Moo Kang

1

1 reference

20 September 2017

Fu Shi Quan

2

1 reference

20 September 2017

Chunzi Huang

3

1 reference

20 September 2017

Lizheng Guo

4

1 reference

20 September 2017

Ling Ye

5

1 reference

20 September 2017

Chinglai Yang

6

1 reference

20 September 2017

Richard W Compans

7

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

331

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

20-32

1 reference

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Selection of recombinant vaccinia viruses on the basis of plaque formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Core structure of gp41 from the HIV envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Site-directed mutagenesis by overlap extension using the polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

gp120: Biologic aspects of structural features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Production and characterization of simian--human immunodeficiency virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

Expression of envelope glycoproteins of human immunodeficiency virus by an insect virus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.005

7 January 2021

10.1016/J.VIROL.2004.10.005

Identifiers

DOI

1 reference

release_tnnde5b6ujabpkihgdvimka3pi

20 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tnnde5b6ujabpkihgdvimka3pi

24 November 2022

mapped directly with Wikidata item

1 reference